New fungus-derived antibiotic: Relief in sight for immunocompromised people

Infections that are treatable in healthy people can often be fatal in immunocompromised individuals (people with a weak immune system), and hence, they require specialized treatment. Eushearilide is already known to be active against a wide range of pathogenic fungi and yeasts, but its antibacterial properties have not been explored. Now, scientists have derived a new compound from eushearilide and demonstrated its antibacterial and antifungal properties. It can be used to treat lung infections, meningitis, and encephalitis.

Read more

Breakthrough in understanding enzymes that make antibiotic for drug-resistant pathogen

One of the WHO's 3 critical priority pathogens, Acinetobacter baumannii, for which new antibiotics are urgently needed is one step closer to being tackled, as researchers have made a breakthrough in understanding the enzymes that assemble the antibiotic enacyloxin.

Read more

Studying proteins moving (relatively) slowly

Proteins keep our organs functioning, regulate our cells and are the targets for medications that treat a number of diseases, including cancers and neurological diseases. Proteins need to move in order to function. But, because the technology they used to watch proteins doesn't allow it, scientists still know very little about such motions at speeds slower than a nanosecond. That changed last month.

Read more

Programmable swarmbots make flexible biological tools

Biomedical engineers have developed a new platform to create biological drugs using specially engineered bacteria that burst and release useful proteins when they sense that their capsule is becoming too crowded.

Read more

Potential target for cardiac fibrosis treatment

A research team has identified a potential target for treating heart failure related to fibrosis. The study looked at an epigenetic 'reader' protein known as BRD4, showing that it serves a central role in regulating the activation of cardiac fibroblasts. They also found that chemical inhibitors of BRD4 potently block cardiac fibroblast activation.

Read more